Logos Global Management »

Lineage Cell Therapeutics In shares owned by Logos Global Management

Quarter-by-quarter ownership of Lineage Cell Therapeutics In (LCTX) shares owned by Logos Global Management from 13F filings

Historical chart of Logos Global Management investment in Lineage Cell Therapeutics In

Tip: Access up to 7 years of quarterly data

All positions including Lineage Cell Therapeutics In held by Logos Global Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Lineage Cell Therapeutics In by Logos Global Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $4.7M 4.7M 1.00
2024-03-31 $9.3M 6.3M 1.48

More positions owned by Logos Global Management

Spdr Ser Tr S&p Biotech Put Option (XBI)
Spdr Ser Tr S&p Biotech Put Option (XBI)
Sarepta Therapeutics (SRPT)
Sarepta Therapeutics Call Option (SRPT)
Apellis Pharmaceuticals Call Option (APLS)
Apellis Pharmaceuticals (APLS)
Structure Therapeutics Sponsored Ads Call Option (GPCR)
Structure Therapeutics Sponsored Ads (GPCR)
Ideaya Biosciences (IDYA)
Ideaya Biosciences (IDYA)
Argenx Se Sponsored Adr (ARGX)
Argenx Se Sponsored Adr (ARGX)
Merus N V (MRUS)
Merus N V (MRUS)
Revolution Medicines (RVMD)

View all positions for Logos Global Management

Top funds holding Lineage Cell Therapeutics In

BlackRock
Vanguard Group
Defender Capital
Logos Global Management
Raffles Associates
Geode Capital Management
State Street Corporation
MAI Wealth Advisors
Bank of America Corporation
DAFNA Capital Management
Bridgeway Capital Management
Royal Bank of Canada
Prescott General Partners
Jpmorgan Chase & Co
Renaissance Technologies

View all funds holding Lineage Cell Therapeutics In